Revolutionizing the Rapid Diagnostics Industry
First Rapid Diagnostic Tests Based on Nano-Immunoglobulin Technology
AlterDiag is collaborating with the Institut Pasteur to develop the first commercial LFT using VHH. Thanks to these innovations, our company will be able to meet unmet medical needs and achieve the minimum levels of quality and performance demanded by healthcare professionals, in order to drive the adoption of these tests.
New Technologies to Meet Market Expectations
Rapid diagnostic tests have proved their usefulness for decades, but the Covid-19 crisis has recently transformed the lateral flow test market, democratizing the use of these diagnostic tools worldwide and by anyone.
However, debate over the quality and performance of these tools, as well as comparison with molecular laboratory tests, continues to slow their adoption by many healthcare professionals. That said, we are convinced that regulatory change, unmet medical needs for RDTs and investment in innovation will change the game in the near future. AlterDiag will drive this adoption of RDTs by all healthcare professionals dealing directly with patients, thanks to innovative new LFTs using nano-immunoglobulin
Nano-immunoglobulin will revolutionize the rapid diagnostic test market
